MDR1 gene polymorphisms are associated with neuropsychiatric adverse effects of mefloquine

Clinical Pharmacology and Therapeutics

Volumn 80, Issue 4, 2006, Pages 367-374

  Aarnoudse, Albert L H J ^a   van Schaik, Ron H N ^a   Dieleman, Jeanne ^a   Molokhia, Mariam ^a   van Riemsdijk, Melanie M ^a   Ligthelm, Robert J ^a   Overbosch, David ^a   van der Heiden, Ilse P ^a   Stricker, Bruno H Ch ^a  

^a Harbour Hospital   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

MEFLOQUINE; MULTIDRUG RESISTANCE PROTEIN 1;

ABNORMAL DREAMING; ADULT; AGED; AGITATION; ARTICLE; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DEPRESSION; DIZZINESS; DRUG BLOOD LEVEL; DRUG INDUCED HEADACHE; DRUG SAFETY; FATIGUE; FEMALE; GENE EXPRESSION; GENE FREQUENCY; GENOTYPE; HAPLOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; INSOMNIA; MALARIA; MALE; MENTAL DISEASE; MENTAL INSTABILITY; NEUROPSYCHIATRY; NORMAL HUMAN; PRIORITY JOURNAL; RISK ASSESSMENT; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL SIGNIFICANCE;

ADULT; AGED; ANTIMALARIALS; CONFIDENCE INTERVALS; CYSTEINE; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENE FREQUENCY; GENES, MDR; GLYCINE; HAPLOTYPES; HUMANS; MALE; MEFLOQUINE; MENTAL DISORDERS; MIDDLE AGED; NERVOUS SYSTEM DISEASES; ODDS RATIO; ORGANIC ANION TRANSPORTERS; P-GLYCOPROTEIN; POLYMORPHISM, GENETIC; REFERENCE VALUES; THREONINE; TRAVEL;

EID: 33749251656     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clpt.2006.07.003     Document Type: Article

References (36)

1. van Riemsdijk M.M., van der Klauw M.M., Pepplinkhuizen L., and Stricker B.H. Spontaneous reports of psychiatric adverse effects to mefloquine in the Netherlands. Br J Clin Pharmacol 44 (1997) 105-106
2. van Riemsdijk M.M., Ditters J.M., Sturkenboom M.C., Tulen J.H., Ligthelm R.J., Overbosch D., et al. Neuropsychiatric events during prophylactic use of mefloquine before travelling. Eur J Clin Pharmacol 58 (2002) 441-445
3. Barrett P.J., Emmins P.D., Clarke P.D., and Bradley D.J. Comparison of adverse events associated with use of mefloquine and combination of chloroquine and proguanil as antimalarial prophylaxis: postal and telephone survey of travellers. BMJ 313 (1996) 525-528
4. van Riemsdijk M.M., Sturkenboom M.C., Ditters J.M., Tulen J.H., Ligthelm R.J., Overbosch D., et al. Low body mass index is associated with an increased risk of neuropsychiatric adverse events and concentration impairment in women on mefloquine. Br J Clin Pharmacol 57 (2004) 506-512
5. Schwartz E., Potasman I., Rotenberg M., Almog S., and Sadetzki S. Serious adverse events of mefloquine in relation to blood level and gender. Am J Trop Med Hyg 65 (2001) 189-192
6. Schlagenhauf P., Steffen R., Lobel H., Johnson R., Letz R., Tschopp A., et al. Mefloquine tolerability during chemoprophylaxis: focus on adverse event assessments, stereochemistry and compliance. Trop Med Int Health 1 (1996) 485-494
7. Hoffmeyer S., Burk O., von Richter O., Arnold H.P., Brockmoller J., Johne A., et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A 97 (2000) 3473-3478
8. Marzolini C., Paus E., Buclin T., and Kim R.B. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther 75 (2004) 13-33
9. Riffkin C.D., Chung R., Wall D.M., Zalcberg J.R., Cowman A.F., Foley M., et al. Modulation of the function of human MDR1 P-glycoprotein by the antimalarial drug mefloquine. Biochem Pharmacol 52 (1996) 1545-1552
10. Morita Y., Sakaeda T., Horinouchi M., Nakamura T., Kuroda K., Miki I., et al. MDR1 genotype-related duodenal absorption rate of digoxin in healthy Japanese subjects. Pharm Res 20 (2003) 552-556
11. Kurata Y., Ieiri I., Kimura M., Morita T., Irie S., Urae A., et al. Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P-glycoprotein. Clin Pharmacol Ther 72 (2002) 209-219
12. Hesselink D.A., van Schaik R.H., van der Heiden I.P., van der Werf M., Gregoor P.J., Lindemans J., et al. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther 74 (2003) 245-254
13. Wald F.D.M., and Mellenbergh G.J. De verkorte versie van de Nederlandse vertaling van de Profile of Mood States (POMS). Ned Tijdschr Psychol 45 (1990) 86-90
14. Baker E.L., Letz R., and Fidler A. A computer-administered neurobehavioral evaluation system for occupational and environmental epidemiology. Rationale, methodology, and pilot study results. J Occup Med 27 (1985) 206-212
15. Letz R. Use of computerized test batteries for quantifying neurobehavioral outcomes. Environ Health Perspect 90 (1991) 195-198
16. Green M.D., Bergqvist Y., Mount D.L., Corbett S., and D'Souza M.J. Improved validated assay for the determination of mefloquine and its carboxy metabolite in plasma, serum and whole blood using solid-phase extraction and high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 727 (1999) 159-165
17. Stephens M., Smith N.J., and Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 68 (2001) 978-989
18. Stephens M., and Donnelly P. A comparison of bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet 73 (2003) 1162-1169
19. fastPHASE: software for haplotype reconstruction, and estimating missing genotypes from population data. Available from URL:http://www.stat.washington.edu/stephens/software.html. Accessed Sept 11, 2006.
20. Barrett J.C., Fry B., Maller J., and Daly M.J. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21 (2005) 263-265
21. Haploview. Available from: URL:http://www.broad.mit.edu/mpghaploview. Accessed Sept 12, 2006.
22. Gerloff T., Schaefer M., Johne A., Oselin K., Meisel C., Cascorbi I., et al. MDR1 genotypes do not influence the absorption of a single oral dose of 1 mg digoxin in healthy white males. Br J Clin Pharmacol 54 (2002) 610-616
23. Kroetz D.L., Pauli-Magnus C., Hodges L.M., Huang C.C., Kawamoto M., Johns S.J., et al. Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene. Pharmacogenetics 13 (2003) 481-494
24. Baudry S., Pham Y.T., Baune B., Vidrequin S., Crevoisier C., Gimenez F., et al. Stereoselective passage of mefloquine through the blood-brain barrier in the rat. J Pharm Pharmacol 49 (1997) 1086-1090
25. Babaoglu M.O., Bayar B., Aynacioglu A.S., Kerb R., Abali H., Celik I., et al. Association of the ABCB1 3435C>T polymorphism with antiemetic efficacy of 5-hydroxytryptamine type 3 antagonists. Clin Pharmacol Ther 78 (2005) 619-626
26. Skarke C., Jarrar M., Schmidt H., Kauert G., Langer M., Geisslinger G., et al. Effects of ABCB1 (multidrug resistance transporter) gene mutations on disposition and central nervous effects of loperamide in healthy volunteers. Pharmacogenetics 13 (2003) 651-660
27. van Riemsdijk M.M., Sturkenboom M.C., Ditters J.M., Ligthelm R.J., Overbosch D., and Stricker B.H. Atovaquone plus chloroguanide versus mefloquine for malaria prophylaxis: a focus on neuropsychiatric adverse events. Clin Pharmacol Ther 72 (2002) 294-301
28. Schuetz E.G., Furuya K.N., and Schuetz J.D. Interindividual variation in expression of P-glycoprotein in normal human liver and secondary hepatic neoplasms. J Pharmacol Exp Ther 275 (1995) 1011-1018
29. Saitoh A., Singh K.K., Powell C.A., Fenton T., Fletcher C.V., Brundage R., et al. An MDR1-3435 variant is associated with higher plasma nelfinavir levels and more rapid virologic response in HIV-1 infected children. AIDS 19 (2005) 371-380
30. Johne A., Kopke K., Gerloff T., Mai I., Rietbrock S., Meisel C., et al. Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene. Clin Pharmacol Ther 72 (2002) 584-594
31. Verstuyft C., Schwab M., Schaeffeler E., Kerb R., Brinkmann U., Jaillon P., et al. Digoxin pharmacokinetics and MDR1 genetic polymorphisms. Eur J Clin Pharmacol 58 (2003) 809-812
32. Morita N., Yasumori T., and Nakayama K. Human MDR1 polymorphism: G2677T/A and C3435T have no effect on MDR1 transport activities. Biochem Pharmacol 65 (2003) 1843-1852
33. Siegmund W., Ludwig K., Giessmann T., Dazert P., Schroeder E., Sperker B., et al. The effects of the human MDR1 genotype on the expression of duodenal P-glycoprotein and disposition of the probe drug talinolol. Clin Pharmacol Ther 72 (2002) 572-583
34. Pauli-Magnus C., Feiner J., Brett C., Lin E., and Kroetz D.L. No effect of MDR1 C3435T variant on loperamide disposition and central nervous system effects. Clin Pharmacol Ther 74 (2003) 487-498
35. Chowbay B., Li H., David M., Bun Cheung Y., and Lee E.J. Meta-analysis of the influence of MDR1 C3435T polymorphism on digoxin pharmacokinetics and MDR1 gene expression. Br J Clin Pharmacol 60 (2005) 159-171
36. Wang D., Johnson A.D., Papp A.C., Kroetz D.L., and Sadee W. Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability. Pharmacogenet Genomics 15 (2005) 693-704